Risperidone in schizophrenia: Is there a role for therapeutic drug monitoring?

Therapeutic Drug Monitoring

Volumn 33, Issue 3, 2011, Pages 275-283

  Seto, Katherine ^a   Dumontet, Jane ^a,b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b FRASER HEALTH AUTHORITY   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Clinical pharmacokinetic monitoring; Risperidone; Therapeutic drug monitoring

Indexed keywords

PALIPERIDONE; RISPERIDONE;

DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL DECISION MAKING; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; DRUG MONITORING; HUMANS; ISOXAZOLES; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA;

EID: 80051797913     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182126d83     Document Type: Review

References (63)

1. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs. 2008;13:479-495.
2. Kane JM. Schizophrenia. N Engl J Med. 1996;334:34-41. (Pubitemid 126528534)
3. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1-56.
4. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635-645.
5. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502-508. (Pubitemid 27527317)
6. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131. (Pubitemid 47529346)
7. Radomsky ED, Haas GL, Mann JJ, et al. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am J Psychiatry. 1999;156: 1590-1595. (Pubitemid 29459992)
8. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150: 1115-1121. (Pubitemid 41773510)
9. Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol. 2007;78:1-39.
10. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med. 1998;42:211-221. (Pubitemid 28529874)
11. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007; 46:359-388. (Pubitemid 46686464)
12. Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994;114:9-23. (Pubitemid 24150515)
13. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:147-151. (Pubitemid 29142884)
14. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172:1703-1711. (Pubitemid 40896865)
15. Ensom MH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34:265-279.
16. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222. (Pubitemid 41070936)
17. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
18. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79-104. (Pubitemid 40139590)
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353: 1209-1223. (Pubitemid 41345943)
20. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006;63: 1079-1087. (Pubitemid 44498387)
21. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35: 51-68. (Pubitemid 29023554)
22. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40. (Pubitemid 23030357)
23. Avenoso A, Facciola G, Salemi M, et al. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversedphase liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000;746:173-181. (Pubitemid 30657933)
24. Nagasaki T, Ohkubo T, Sugawara K, et al. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia. J Pharm Biomed Anal. 1999;19: 595-601. (Pubitemid 29073517)
25. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Sci Appl. 1997;698:209-216. (Pubitemid 27412523)
26. Titier K, Deridet E, Cardone E, et al. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772:373-378. (Pubitemid 34499585)
27. Frahnert C, Rao ML, Grasmader K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 794:35-47. (Pubitemid 36897624)
28. Bhatt J, Subbaiah G, Singh S. Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid Commun Mass Spectrom. 2006;20:2109-2114. (Pubitemid 44049037)
29. Aravagiri M, Marder SR, Wirshing D, et al. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry. 1998;31:102-109. (Pubitemid 28255495)
30. Aravagiri M, Marder SR, Van Putten T, et al. Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. J Pharm Sci. 1993;82:447-449. (Pubitemid 23150444)
31. Aravagiri M, Marder SR. Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. J Mass Spectrom. 2000;35:718-724. (Pubitemid 30345231)
32. Cabovska B, Cox SL, Vinks AA. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852: 497-504. (Pubitemid 46830144)
33. De Meulder M, Remmerie BM, de Vries R, et al. Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;870:8-16.
34. Lostia AM, Mazzarini L, Pacchiarotti I, et al. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther Drug Monit. 2009;31:475-481.
35. Moody DE, Laycock JD, Huang W, et al. A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma. J Anal Toxicol. 2004;28:494-497. (Pubitemid 39150372)
36. Remmerie BM, Sips LL, de Vries R, et al. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;783:461-472. (Pubitemid 35447997)
37. Le Moing JP, Edouard S, Levron JC. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1993;614: 333-339. (Pubitemid 23142091)
38. Balant-Gorgia AE, Gex-Fabry M, Genet C, et al. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit. 1999;21:105-115. (Pubitemid 29077463)
39. Price MC, Hoffman DW. Therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in serum with solid-phase extraction and high-performance liquid chromatography. Ther Drug Monit. 1997;19: 333-337. (Pubitemid 28053490)
40. Schatz DS, Saria A. Simultaneous determination of paroxetine, risperidone and 9-hydroxyrisperidone in human plasma by highperformance liquid chromatography with coulometric detection. Pharmacology. 2000;60:51-56. (Pubitemid 30025954)
41. Woestenborghs R, Lorreyne W, Van Rompaey F, et al. Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. J Chromatogr. 1992;583: 223-230.
42. Olesen OV, Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20:380-384. (Pubitemid 28359985)
43. Aravagiri M, Marder SR, Nuechterlein KH, et al. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003; 25:657-664. (Pubitemid 37499299)
44. Yoshimura R, Ueda N, Nakamura J. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology. 2001;44:129-133. (Pubitemid 34701619)
45. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001;23:223-227. (Pubitemid 32476548)
46. Riedel M, Schwarz MJ, Strassnig M, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci. 2005;255:261-268. (Pubitemid 41187035)
47. Mauri MC, Laini V, Boscati L, et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry. 2001;16:57-63. (Pubitemid 32171333)
48. Odou P, Levron JC, Luyckx M, et al. Risperidone drug monitoring: a useful clinical tool? Clin Drug Invest. 2000;19:283-292.
49. Aymard N, Viala A, Clement MN, et al. Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:975-988. (Pubitemid 35245566)
50. Kakihara S, Yoshimura R, Shinkai K, et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol. 2005;20:71-78. (Pubitemid 40354395)
51. Lee HS, Tan CH, Khoo YM, et al. Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore - a preliminary report. Br J Clin Pharmacol. 1999;47:460-461. (Pubitemid 29161283)
52. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl). 2001;153:238-243. (Pubitemid 32127893)
53. Bozina N, Jovanovic N, Lovric M, et al. Clinical significance of a CYP2D6 poor metabolizer - a patient with schizophrenia on risperidone treatment. Ther Drug Monit. 2008;30:748-751.
54. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257-268. (Pubitemid 23294526)
55. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15-27.
56. Kang RH, Jung SM, Kim KA, et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol. 2009;29:272-277.
57. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265. (Pubitemid 39587052)
58. Livingston MG. Risperidone. Lancet. 1994;343:457-460. (Pubitemid 24059591)
59. Nishikage H, Nakanishi T, Takamitsu Y, et al. Sequential changes in the plasma concentration of risperidone following intentional overdose. Clin Neuropharmacol. 2002;25:307-309. (Pubitemid 36025269)
60. Castberg I, Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit. 2005;27:103-106. (Pubitemid 40189982)
61. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol. 2005;25:527-532. (Pubitemid 41669043)
62. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22:481-485. (Pubitemid 30622123)
63. Kapur S, Agid O, Mizrahi R, et al. How antipsychotics work-from receptors to reality. NeuroRx. 2006;3:10-21. (Pubitemid 43276632)